Jörn Markus Schattenberg
1,073 works · 35,571 citations · h-index 83
Top works
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
- A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
- Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
- Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- Advancing the global public health agenda for NAFLD: a consensus statement
- Jnk1 but not jnk2 promotes the development of steatohepatitis in mice†
- Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis
- A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
- Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
- Hepatocyte CYP2E1 Overexpression and Steatohepatitis Lead to Impaired Hepatic Insulin Signaling
- Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
- The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease
- Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
- Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
- Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis
- Liver injury in COVID‐19: The current evidence